TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Life After STroke - the LAST Study. A Norwegian Multi Centre Randomized Controlled Trial
Brief Summary: The LAST study is a Norwegian multi site randomised controlled trial that intends to assess the effect of a long term follow up program after stroke. The program consists of a coordinating physiotherapist who will encourage and motivate included patients to perform at least 60 minutes of intensive motor training every week and 30 minutes of physical activity every day for 18 months after inclusion. The primary hypothesis is that patients receiving a long term follow up program after stroke will have better motor function at end of follow up than patients receiving standard care. A total of 390 home dwelling stroke patients living in the municipality of Trondheim, Asker and Bærum will be included at the out-patient clinic at St. Olavs Hospital or Bærum Hospital three months after their stroke. Included patients will be randomised to an intervention group receiving the long term follow up program or to a control group receiving standard care. Motor function, mental health and physical functioning in daily life will be assessed at inclusion and 18 months later. The LAST study is funded by the Norwegian Research Council, the Norwegian University of Science and Technology and the Central Norway Regional Health Authority and will conclude at the end of 2015.


Options:
A: Arm Label: Education & training consultation; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Bilateral movement training | Arm Label: Bilateral movement training; Type: EXPERIMENTAL; Interventions: Procedure: Bilateral movement training | Intervention Type: PROCEDURE; Name: Bilateral movement training; Assigned to Arm(s): Bilateral movement training, Education & training consultation
B: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
C: Arm Label: Long term follow up program; Type: EXPERIMENTAL; Interventions: Behavioral: Long term follow up by a coordinating physiotherapist | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Long term follow up by a coordinating physiotherapist; Assigned to Arm(s): Long term follow up program | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: ICoreDIST; Type: EXPERIMENTAL; Interventions: Procedure: ICoreDIST | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Intervention Type: PROCEDURE; Name: ICoreDIST; Assigned to Arm(s): ICoreDIST | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 1•DAY ACUVUE® TruEye™ Brand Contact Lenses & 1•DAY ACUVUE® MOIST® Brand Contact Lenses With LACREON® TECHNOLOGY Daily Disposable Performance Overview Registry -TEMPO Study
Brief Summary: This study is an observational registry of patients who have recently been prescribed 1•DAY ACUVUE® TruEye® or 1•DAY ACUVUE® MOIST® Brand Contact Lenses with LACREON® TECHNOLOGY.


Options:
A: Arm Label: 1-Day ACUVUE TruEye contact lens users; Type: N/A; Interventions: Device: narafilcon B daily disposable soft contact lenses | Arm Label: 1-Day ACUVUE MOIST contact lens users; Type: N/A; Interventions: Device: etafilcon A daily disposable soft contact lenses | Intervention Type: DEVICE; Name: narafilcon B daily disposable soft contact lenses; Assigned to Arm(s): 1-Day ACUVUE TruEye contact lens users | Intervention Type: DEVICE; Name: etafilcon A daily disposable soft contact lenses; Assigned to Arm(s): 1-Day ACUVUE MOIST contact lens users
B: Arm Label: ReNu Multiplus and lotrafilcon A lenses; Type: ACTIVE_COMPARATOR; Interventions: Device: lotrafilcon A contact lenses, Device: Renu Multiplus | Arm Label: Clear Care solution and lotrafilcon A lenses; Type: ACTIVE_COMPARATOR; Interventions: Device: lotrafilcon A contact lenses, Device: Clear Care | Intervention Type: DEVICE; Name: lotrafilcon A contact lenses; Assigned to Arm(s): Clear Care solution and lotrafilcon A lenses, ReNu Multiplus and lotrafilcon A lenses | Intervention Type: DEVICE; Name: Renu Multiplus; Assigned to Arm(s): ReNu Multiplus and lotrafilcon A lenses | Intervention Type: DEVICE; Name: Clear Care; Assigned to Arm(s): Clear Care solution and lotrafilcon A lenses
C: Arm Label: Presbyope group; Type: OTHER; Interventions: Device: Etafilcon A, Device: Nelfilcon A, Device: Nesofilcon A, Device: Somofilcon A, Device: 58% Poly-HEMA | Arm Label: Non-Presbyope group; Type: OTHER; Interventions: Device: Etafilcon A, Device: Nelfilcon A, Device: Omafilcon A | Intervention Type: DEVICE; Name: Etafilcon A; Assigned to Arm(s): Non-Presbyope group, Presbyope group | Intervention Type: DEVICE; Name: Etafilcon A; Assigned to Arm(s): Presbyope group | Intervention Type: DEVICE; Name: Nelfilcon A; Assigned to Arm(s): Presbyope group | Intervention Type: DEVICE; Name: Nesofilcon A; Assigned to Arm(s): Presbyope group | Intervention Type: DEVICE; Name: Nelfilcon A; Assigned to Arm(s): Non-Presbyope group | Intervention Type: DEVICE; Name: Etafilcon A; Assigned to Arm(s): Non-Presbyope group | Intervention Type: DEVICE; Name: Somofilcon A; Assigned to Arm(s): Presbyope group | Intervention Type: DEVICE; Name: 58% Poly-HEMA; Assigned to Arm(s): Presbyope group | Intervention Type: DEVICE; Name: Omafilcon A; Assigned to Arm(s): Non-Presbyope group
D: Arm Label: Hyperosmolarity group; Type: EXPERIMENTAL; Interventions: Other: Daily-disposable soft contact lens | Arm Label: Normal osmolarity; Type: EXPERIMENTAL; Interventions: Other: Daily-disposable soft contact lens | Intervention Type: OTHER; Name: Daily-disposable soft contact lens; Assigned to Arm(s): Hyperosmolarity group, Normal osmolarity

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain
Brief Summary: Although national expenditures on back pain treatments have increased substantially over the past decade, the health and functional status of persons suffering from back pain has deteriorated. This trial will evaluate the effectiveness, and cost-effectiveness, of a safe and relatively inexpensive "mind-body" therapy that has the potential to provide relief to some of the millions of Americans who continue to suffer from chronic back pain.


Options:
A: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
B: Arm Label: Cognitive Behavioral Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Mindfulness-Based Stress Reduction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Stress Reduction | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): Mindfulness-Based Stress Reduction
C: Arm Label: CBT plus relaxation response; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation response and cognitive behavioral therapy | Arm Label: Relaxation Response; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation response | Arm Label: Education; Type: PLACEBO_COMPARATOR; Interventions: Other: RA education | Intervention Type: BEHAVIORAL; Name: Relaxation response and cognitive behavioral therapy; Assigned to Arm(s): CBT plus relaxation response | Intervention Type: BEHAVIORAL; Name: Relaxation response; Assigned to Arm(s): Relaxation Response | Intervention Type: OTHER; Name: RA education; Assigned to Arm(s): Education
D: Arm Label: Integrative Medicine Group Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Integrative Medicine Group Visits | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrative Medicine Group Visits; Assigned to Arm(s): Integrative Medicine Group Visits

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients
Brief Summary: Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical interstitial compartment of the kidney where most of the scarring occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney diseases.


Options:
A: Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
B: Arm Label: Metoprolol; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol | Arm Label: Placebo for Metoprolol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: Candesartan | Arm Label: Placebo for Candesartan; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol; Assigned to Arm(s): Metoprolol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for Metoprolol | Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for Candesartan
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Losartan 100mg; Type: EXPERIMENTAL; Interventions: Drug: Losartan 100mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Losartan 100mg; Assigned to Arm(s): Losartan 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes
Brief Summary: The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ganirelix | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: triptorelin | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): 2
B: Arm Label: GnRH agonist; Type: EXPERIMENTAL; Interventions: Drug: Triptorelin | Arm Label: GnRH antagonist; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetrorelix | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): GnRH agonist | Intervention Type: DRUG; Name: Cetrorelix; Assigned to Arm(s): GnRH antagonist
C: Arm Label: Follicular Estrogen, Antagonist, IVF; Type: EXPERIMENTAL; Interventions: Drug: estradiol valerate | Arm Label: long IVF protocol; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol valerate | Intervention Type: DRUG; Name: estradiol valerate; Assigned to Arm(s): Follicular Estrogen, Antagonist, IVF, long IVF protocol
D: Arm Label: Observational Cohort; Type: N/A; Interventions: Drug: ganirelix | Arm Label: Historical Controls; Type: N/A; Interventions: Drug: GnRH agonist | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): Observational Cohort | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Historical Controls

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial
Brief Summary: The purpose of this randomized intervention study is to investigate the effects and biological mechanisms of a supervised 12-week progressive resistance training on fatigue and immunological and inflammatory biomarkers in breast cancer patients during adjuvant radiotherapy. To determine the effect of the exercise itself beyond potential psychosocial effects due to attention by trainers or the group support, patients in the control group have a comparable training schedule (i.e. 60 min, twice a week, for 12 weeks) but with relaxation training (Jacobsen method).


Options:
A: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
B: Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Pedometer; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Exercise guidebook; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial
Brief Summary: The purpose of this randomized intervention study is to investigate the effects and biological mechanisms of a supervised 12-week progressive resistance training on fatigue and immunological and inflammatory biomarkers in breast cancer patients during adjuvant radiotherapy. To determine the effect of the exercise itself beyond potential psychosocial effects due to attention by trainers or the group support, patients in the control group have a comparable training schedule (i.e. 60 min, twice a week, for 12 weeks) but with relaxation training (Jacobsen method).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
D: Intervention Type: PROCEDURE; Name: Memory Training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial
Brief Summary: The purpose of this randomized intervention study is to investigate the effects and biological mechanisms of a supervised 12-week progressive resistance training on fatigue and immunological and inflammatory biomarkers in breast cancer patients during adjuvant radiotherapy. To determine the effect of the exercise itself beyond potential psychosocial effects due to attention by trainers or the group support, patients in the control group have a comparable training schedule (i.e. 60 min, twice a week, for 12 weeks) but with relaxation training (Jacobsen method).


Options:
A: Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: RePCa A | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: RePCa A | Intervention Type: BEHAVIORAL; Name: RePCa A; Assigned to Arm(s): Control, Rehabilitation
B: Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Training Group
C: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Behavior Change | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Behavior Change; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Brief Summary: The purpose of this study is to compare the combination of pemetrexed and gefitinib versus gefitinib alone, in terms of progression-free survival. This study is in participants who have stage IV non squamous NSCLC with activating epidermal growth factor mutations and who have not had any previous chemotherapy for stage IV disease.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
B: Arm Label: Pemetrexed + Cisplatin + Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib
C: Arm Label: 250 mg Gefitinib/500 mg Pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib, Drug: Pemetrexed | Arm Label: 250 mg Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 250 mg Gefitinib, 250 mg Gefitinib/500 mg Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): 250 mg Gefitinib/500 mg Pemetrexed
D: Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Brief Summary: The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.


Options:
A: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: ALKS 9072; Type: EXPERIMENTAL; Interventions: Drug: ALKS 9072 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ALKS 9072; Assigned to Arm(s): ALKS 9072 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D